Experimental cell therapy targets Hard-to-Treat kidney cancer
NCT ID NCT04696731
First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 29 times
Summary
This early-phase study tests an experimental cell therapy called ALLO-316 in adults with advanced or metastatic clear cell kidney cancer who have already tried standard treatments. Participants receive the therapy after a short course of chemotherapy to prepare their immune system. The main goals are to check safety and find the best dose for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
-
UCLA Medical Center
Los Angeles, California, 90095, United States
-
UCSF Medical Center
San Francisco, California, 94143, United States
-
Yale School of Medicine
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.